GlassScriptPhysician profile
Heidi Hemak
NPI 1669549788
$11,376.92
in general payments reported to CMS, 2019-2025
31 companies · $2,065 in 2025
The $2,065 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,971 · 2022: $2,688 · 2023: $2,143 · 2024: $2,509 · 2025: $2,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,580 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,580.21 |
| Education | $137.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,102.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,462.73 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $1,219.31 | 2021-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $824.09 | 2021-2025 | Livdelzi, Epclusa |
| Ardelyx, INC. | $626.83 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $554.33 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $514.52 | 2022-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $475.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $459.54 | 2021-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $372.86 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $371.92 | 2024-2025 | Zenpep, Vowst |
| Ironwood Pharmaceuticals, INC | $321.00 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $285.74 | 2021-2023 | |
| Lilly USA, LLC | $271.05 | 2023-2024 | Omvoh |
| Pfizer INC. | $241.58 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $223.80 | 2021-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $172.43 | 2021-2023 | Ocaliva |
| Celgene Corporation | $132.13 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $131.48 | 2024-2025 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $126.83 | 2021-2023 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $117.37 | 2024-2025 | Voquezna |
| Organon LLC | $53.46 | 2025 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.67 | 2023-2024 | Cyltezo |
| Convatec INC. | $31.85 | 2024 | |
| Redhill Biopharma INC. | $31.10 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Amgen INC. | $29.30 | 2023 | Amjevita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.02 | 2023 | |
| Radius Health, INC. | $17.13 | 2024 | Tymlos |
| Axonics, INC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Hemak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.